{"title":"Timing influences detection of anti-nephrin antibodies in recurrent FSGS.","authors":"Marie-Camille Lafargue, Leonardo V Riella","doi":"10.1172/JCI212285","DOIUrl":"https://doi.org/10.1172/JCI212285","url":null,"abstract":"","PeriodicalId":15469,"journal":{"name":"Journal of Clinical Investigation","volume":"136 22","pages":""},"PeriodicalIF":14.3,"publicationDate":"2026-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149417580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Neutrophils close the loop: self-sustaining splenic myelopoiesis in cancer.","authors":"Hongpeng Jia","doi":"10.1172/JCI213855","DOIUrl":"https://doi.org/10.1172/JCI213855","url":null,"abstract":"<p><p>Cancer-associated extramedullary hematopoiesis is increasingly recognized as a systemic mechanism of immune evasion. Although the spleen is an important site of tumor-induced myelopoiesis, how this process is locally maintained remains incompletely understood. In this issue of the JCI, Zhu and colleagues identify a self-reinforcing circuit between tumor-associated neutrophils and splenic hematopoietic stem and progenitor cells (HSPCs). They show that neutrophil-derived, NOX2-dependent ROS activated forkhead box O1 (FOXO1) in neighboring HSPCs, inducing dynamin-related protein 1 dependent (DRP1-dependent) mitochondrial fission and a myeloid-biased, granulocyte-macrophage CSF-producing (GM-CSF-producing) progenitor state. The resulting neutrophil progeny further reinforced oxidative stress, thereby sustaining immunosuppressive myelopoiesis in the spleen. Disruption of this circuit through genetic, pharmacologic, or spleen-directed interventions reduced suppressive myeloid cell production, enhanced cytotoxic T cell activity, and restrained tumor growth. These findings establish mature neutrophils as active regulators of pathological splenic hematopoiesis and identify the neutrophil/ROS/FOXO1/DRP1 axis as a potential therapeutic target in cancer.</p>","PeriodicalId":15469,"journal":{"name":"Journal of Clinical Investigation","volume":"136 22","pages":""},"PeriodicalIF":14.3,"publicationDate":"2026-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149417578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sindhuri Prakash, Nicholas J Steers, Yifu Li, Elena Sanchez-Rodriguez, Miguel Verbitsky, Isabel Robbins, Jenna Simpson, Sharvari Pathak, Milan Raska, Colin Reily, Anna Ng, Judy Liang, Natalia DeMaria, Amanda Katiraei, Kelsey O Stevens, Clara Fischman, Samantha Shapiro, Swetha Kodali, Jason McCutchan, Heekuk Park, Djamila Eliby, Marco Delsante, Landino Allegri, Enrico Fiaccadori, Monica Bodria, Maddalena Marasa, Elizabeth Raveche, Bruce A Julian, Anne-Catrin Uhlemann, Krzysztof Kiryluk, Hong Zhang, Vivette D D'Agati, Simone Sanna-Cherchi, Jan Novak, Ali G Gharavi
{"title":"Corrigendum to Loss of GalNAc-T14 links O-glycosylation defects to alterations in B cell homing in IgA nephropathy.","authors":"Sindhuri Prakash, Nicholas J Steers, Yifu Li, Elena Sanchez-Rodriguez, Miguel Verbitsky, Isabel Robbins, Jenna Simpson, Sharvari Pathak, Milan Raska, Colin Reily, Anna Ng, Judy Liang, Natalia DeMaria, Amanda Katiraei, Kelsey O Stevens, Clara Fischman, Samantha Shapiro, Swetha Kodali, Jason McCutchan, Heekuk Park, Djamila Eliby, Marco Delsante, Landino Allegri, Enrico Fiaccadori, Monica Bodria, Maddalena Marasa, Elizabeth Raveche, Bruce A Julian, Anne-Catrin Uhlemann, Krzysztof Kiryluk, Hong Zhang, Vivette D D'Agati, Simone Sanna-Cherchi, Jan Novak, Ali G Gharavi","doi":"10.1172/JCI214000","DOIUrl":"https://doi.org/10.1172/JCI214000","url":null,"abstract":"","PeriodicalId":15469,"journal":{"name":"Journal of Clinical Investigation","volume":"136 22","pages":""},"PeriodicalIF":14.3,"publicationDate":"2026-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149417570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Shijie Li, Nan Li, Xiangming Liu, Yueqi Cai, Mukai Wang, Huimin Wang, Yang-Xin Fu, Zaopeng Yang
{"title":"Logic-gated T cell engager with mutant IL-2 potentiates antitumor responses without cytotoxicity in solid tumor models.","authors":"Shijie Li, Nan Li, Xiangming Liu, Yueqi Cai, Mukai Wang, Huimin Wang, Yang-Xin Fu, Zaopeng Yang","doi":"10.1172/JCI204657","DOIUrl":"https://doi.org/10.1172/JCI204657","url":null,"abstract":"<p><p>T cell engagers (TCEs) have achieved transformative success in B cell malignancies but show limited efficacy in solid tumors with severe toxicity. We propose that TCR signaling without IL-2 might limit the function of tumor-infiltrating lymphocytes (TILs). Here, we showed that insufficient IL-2 signaling is a key bottleneck for sustaining TCE-induced T cell function. Although exogenous IL-2 enhances TCE efficacy, its systemic administration causes more severe toxicity. We engineered a protease-activatable dual-variable domain (DVD) as a pro-antibody to reduce αCD3 off-tumor toxicity. Furthermore, we designed 3 additional mutations for IL-2 (3E) with markedly reduced receptor affinity, which remained inactive in the periphery. By coengineering the DVD and 3E into a single pro-drug molecule (DVD-3E), we achieved conditional IL-2 and TCR cosignaling strictly dependent on cis CD3 engagement within the tumor microenvironment (TME) upon protease cleavage. This logic-gated design restricted both TCE and cytokine activity to the TME, enabling potent antitumor responses without systemic toxicity. Mechanistically, DVD-3E enhanced not only the persistence and effector function of preexisting intratumoral T cells but also expanded TCF1+ TILs, mitigating exhaustion and enabling durable systemic immunity. These findings define a new design principle for logic-gated TCEs that achieve a favorable balance between efficacy and safety, offering a strategy to overcome current therapeutic resistance.</p>","PeriodicalId":15469,"journal":{"name":"Journal of Clinical Investigation","volume":"136 22","pages":""},"PeriodicalIF":14.3,"publicationDate":"2026-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149417575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Anthony C Cruz, Krisztian Csomos, Hiroto Nakano, Boglarka Ujhazi, Paul M Panipinto, Sophia R Chou, Marissa Krantz, Emily D Rosenbaum, Mariana Correia Marques, Christopher Felicelli, Tian-Min Fu, Dirk Foell, Rae Sm Yeung, Pamela F Weiss, Faiza Naz, Ly-Lan Bergeron, Michelle Millwood, Carol Lake, Keisuke Nagao, Paul Schaughency, Vicky Chen, Justin Lack, Emely L Verweyen, Grant Schulert, Kang Yu, Stefania Dell'Orso, Hao Wu, Zuoming Deng, Davide Randazzo, Michael J Ombrello
{"title":"Golgi-retained TNFR1 variants induce stress-driven inflammation in a subset of systemic juvenile idiopathic arthritis.","authors":"Anthony C Cruz, Krisztian Csomos, Hiroto Nakano, Boglarka Ujhazi, Paul M Panipinto, Sophia R Chou, Marissa Krantz, Emily D Rosenbaum, Mariana Correia Marques, Christopher Felicelli, Tian-Min Fu, Dirk Foell, Rae Sm Yeung, Pamela F Weiss, Faiza Naz, Ly-Lan Bergeron, Michelle Millwood, Carol Lake, Keisuke Nagao, Paul Schaughency, Vicky Chen, Justin Lack, Emely L Verweyen, Grant Schulert, Kang Yu, Stefania Dell'Orso, Hao Wu, Zuoming Deng, Davide Randazzo, Michael J Ombrello","doi":"10.1172/JCI196975","DOIUrl":"https://doi.org/10.1172/JCI196975","url":null,"abstract":"<p><p>Systemic juvenile idiopathic arthritis (sJIA) is a complex inflammatory disease characterized by recurrent fevers, arthritis, and systemic hyperinflammation; however, its underlying etiology remains poorly understood. Tumor necrosis factor receptor 1 (TNFR1, TNFRSF1A), the prototypical TNF superfamily receptor, signals through its ligand (tumor necrosis factor, TNF) to activate NF-κB-dependent proinflammatory pathways while also promoting cell death. Through family-based and targeted sequencing, we identified multiple rare TNFRSF1A variants, including a de novo truncating variant in a patient with monophasic sJIA. Integrating single cell RNA-seq with in vitro and ex vivo functional assays, we uncovered a patient-specific, unique monocyte population marked by high inflammatory cytokine production. These cells display impaired endosomal and Golgi trafficking, dysregulated autophagy, and increased markers of cellular stress and immune activation. Confocal microscopy revealed aberrant TNFR1 retention within the Golgi apparatus. These monocytes were refractory to LPS-induced cell death, maintained a M1-like inflammatory phenotype and produced proinflammatory cytokines even at steady state. Despite conferring a loss of function in TNFR1 signaling, these variants paradoxically drive a hyperinflammatory phenotype. We propose that this results from combined effects of reduced TNFR1 signaling and cellular stress induced by retention of the mutant receptor in the Golgi.</p>","PeriodicalId":15469,"journal":{"name":"Journal of Clinical Investigation","volume":"136 22","pages":""},"PeriodicalIF":14.3,"publicationDate":"2026-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149417573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ludan Zhang, Shumin Yin, Wei Hou, Dan Yang, Yiyuan Jia, Yun Liu, Yan Wang, Sirui Zhao, Xiaoyan Gao, Xiaolin Sun, Xiao Lu, Jianyong Li, Ming Chu, Xiaoqing Xiong, Huayuan Zhu, Juejin Wang
{"title":"C/EBP-β-mediated upregulation of CaV1.2 calcium channel increases arterial constriction in mice with ibrutinib-associated hypertension.","authors":"Ludan Zhang, Shumin Yin, Wei Hou, Dan Yang, Yiyuan Jia, Yun Liu, Yan Wang, Sirui Zhao, Xiaoyan Gao, Xiaolin Sun, Xiao Lu, Jianyong Li, Ming Chu, Xiaoqing Xiong, Huayuan Zhu, Juejin Wang","doi":"10.1172/JCI203386","DOIUrl":"https://doi.org/10.1172/JCI203386","url":null,"abstract":"<p><p>Ibrutinib, a Bruton's tyrosine kinase inhibitor, is indicated for treating chronic lymphocytic leukemia (CLL), but hypertension is a common cardiovascular adverse event. Previous studies have linked ibrutinib to cardiac events through dysregulated intracellular calcium handling, but the mechanisms underlying ibrutinib-associated hypertension remain largely unknown. Here, we followed up 225 CLL patients receiving ibrutinib or managed with watch-and-wait strategy, and identified ibrutinib as an independent risk factor for hypertension. In mice, ibrutinib elevated arterial blood pressure (BP) without structural remodeling of small arteries, and it potentiated K+-induced vasoconstriction. In vascular smooth muscle cells (VSMCs), ibrutinib upregulated CaV1.2 channel expression and function, as evidenced by enhanced CaV1.2 currents and K+-triggered-[Ca2+]i elevation. Mechanistically, ibrutinib suppressed casein kinase 2 (CK2)-mediated HSP90β phosphorylation, and stabilized C/EBP-β, which bound to the promoter of Cacna1c gene and drove CaV1.2 transcription. Significantly, C/EBP-β knockdown attenuated ibrutinib-induced CaV1.2 hyperactivity and vasoconstriction. Collectively, these findings reveal a CK2-HSP90β-C/EBP-β-CaV1.2 signaling cascade through which ibrutinib enhances vascular Ca2+ influx and vasoconstriction, thereby elevating arterial BP. Thus, this study nominates C/EBP-β as a therapeutic target for ibrutinib-associated hypertension.</p>","PeriodicalId":15469,"journal":{"name":"Journal of Clinical Investigation","volume":" ","pages":""},"PeriodicalIF":14.3,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149406481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Epigenetic regulation of DOT1L methyltransferase activityremodels lipid metabolism to alleviate ferroptosis-induced liver injury.","authors":"Jia-Ming Hu, Shuo Liu, Zheng-Ze Pan, Yi-Jia Gao, Wei-Wei Cui, Xiao Zhuang, Rong Wang, Ya-Jing Han, Jia-Xing Liu, Xiang-Chuang Fan, Dan-Dan Song, Zi-Yang Zhang, Wan-Yang Sun, Zong-Li Zhang, Rong-Rong He, Yun-Fei Xu, Wei Gu, Chang Pan, Bo Chu","doi":"10.1172/JCI205758","DOIUrl":"https://doi.org/10.1172/JCI205758","url":null,"abstract":"<p><p>Epigenetic modifications contribute to lipid-related disorders by modulating the expression of key genes involved in lipid metabolism. Accumulating evidence suggests that lipid metabolism-mediated ferroptosis drives the progression of metabolic associated steatohepatitis (MASH) and liver injury. However, whether epigenetic mechanisms remodel lipid metabolism to regulate ferroptosis-induced liver damage remains unclear. Here, through pharmacological screening of epigenetics-related compounds and CRISPR-Cas9-based screening targeting epigenetic factors, we identified DOT1 Like Histone Lysine Methyltransferase (DOT1L) as a key sensitizer of hepatocytes to ferroptosis and subsequent liver injury, whereas inhibition of DOT1L reverses the phenomenon. DOT1L loss remodeled the phospholipid landscape by decreasing PUFA-containing phospholipids while increasing monounsaturated and lysophospholipid species. Mechanistically, DOT1L depletion reduced H3K79me1 and H3K79me2 occupancy at the PLA2G7, ALDH3B1, and PLCXD3 loci, particularly across gene-body regions, while increasing promoter-proximal accessibility and expression of these phospholipid-remodeling genes. These genes suppress ferroptosis by reducing the levels of phospholipids containing polyunsaturated fatty acids (PL-PUFAs). Furthermore, we demonstrated that AMPK phosphorylates DOT1L at Ser786, weakens its association with AF9, and suppresses H3K79 methyltransferase activity and ferroptosis sensitivity. Collectively, our findings reveal the AMPK-DOT1L-H3K79 methylation axis as a novel lipid metabolic pathway that regulates ferroptosis and maintains hepatic homeostasis, offering new therapeutic insights for ferroptosis-related liver injury.</p>","PeriodicalId":15469,"journal":{"name":"Journal of Clinical Investigation","volume":" ","pages":""},"PeriodicalIF":14.3,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149406482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Daniel P Gale, Detlef Böckenhauer, Maryline Fresquet, Emily Williams, Conor J Sugden, Melanie My Chan, Katie Wong, Meei-Hua Lin, Kohei Omachi, Konstantinos Tzoumkas, Lior Horonchik, Roger B Clark, Jochen Reiser, Peter Mundel, Uwe Andag, Jeffrey H Miner, Rachel Lennon, Nicole Endlich, Behzad Najafian, Sumit Aggarwal
{"title":"Phase 2a study of readthrough therapy in nonsense mutation Alport syndrome.","authors":"Daniel P Gale, Detlef Böckenhauer, Maryline Fresquet, Emily Williams, Conor J Sugden, Melanie My Chan, Katie Wong, Meei-Hua Lin, Kohei Omachi, Konstantinos Tzoumkas, Lior Horonchik, Roger B Clark, Jochen Reiser, Peter Mundel, Uwe Andag, Jeffrey H Miner, Rachel Lennon, Nicole Endlich, Behzad Najafian, Sumit Aggarwal","doi":"10.1172/JCI208623","DOIUrl":"https://doi.org/10.1172/JCI208623","url":null,"abstract":"<p><strong>Background: </strong>Alport syndrome (AS), a Mendelian kidney disease, is caused by pathogenic mutations in the X- linked gene COL4A5 and autosomal genes COL4A3, COL4A4 encoding the alpha-chains secreted by podocytes to form the glomerular basement membrane collagen α3α4α5(IV) trimer. Nonsense mutations in autosomal recessive and hemizygous X-linked Alport syndrome (NMAS) introduce premature termination codons and have a particularly poor prognosis, with kidney failure typically occurring by early adulthood. There is substantial unmet need for effective therapy for AS, which has no approved treatments. Exaluren (formerly ELX-02) is a novel eukaryotic ribosome-targeted glycoside that is preferentially taken up by kidney cells and promotes readthrough of premature but not native termination codons, allowing full-length protein production.</p><p><strong>Methods: </strong>In this proof-of-mechanism study, three patients (ages 12-18) with autosomal recessive Alport syndrome and a COL4A4 premature termination codon received daily subcutaneous exaluren (0.75 mg/kg) for 8 weeks.</p><p><strong>Results: </strong>Safety and tolerability assessments (primary endpoint) revealed no new signals. Secondary endpoints assessed by kidney biopsy before and after treatment revealed increased collagen α3(IV), α4(IV) and α5(IV) abundance, physiologically localised collagen α5(IV), and partially improved podocyte morphology in all participants, with changes directionally concordant with increased collagen α3α4(IV) abundance. Proteinuria changes were inconsistent with interpretation limited by intra-patient variability and the short treatment duration; hematuria persisted in all participants.</p><p><strong>Conclusion: </strong>These findings provide first-in-human evidence of exaluren-mediated collagen IV readthrough and justify further trials in Alport syndrome and other nonsense mutation-driven kidney diseases, which often cause early-onset kidney failure.</p><p><strong>Trial registration: </strong></p><p><strong>Clinicaltrials: </strong>gov Identifier: NCT05448755.</p>","PeriodicalId":15469,"journal":{"name":"Journal of Clinical Investigation","volume":" ","pages":""},"PeriodicalIF":14.3,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149406483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}